CL-216303 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H530121

CAS#: 86215-36-3

Description: A dopamine transporter inhibitor and a 5-HT inhibitor potentially for the treatment of depression.

Chemical Structure

img
CL-216303 HCl
CAS# 86215-36-3
Instruction

Theoretical Analysis

Hodoodo Cat#: H530121
Name: CL-216303 HCl
CAS#: 86215-36-3
Chemical Formula: C11H12Cl3N
Exact Mass: 0.00
Molecular Weight: 264.570
Elemental Analysis: C, 49.94; H, 4.57; Cl, 40.20; N, 5.29

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CL-216303; DOV-216303; CL216303; DOV216303; CL 216303; DOV 216303

IUPAC/Chemical Name: 3-Azabicyclo(3.1.0)hexane, 1-(3,4-dichlorophenyl)-, hydrochloride (1:1)

InChi Key: KAGBHVBIOJBGBD-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H11Cl2N.ClH/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11;/h1-3,8,14H,4-6H2;1H

SMILES Code: ClC1=CC=C(C23CNCC2C3)C=C1Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 66504-40-3(DOV-216303 Free base) 86215-36-3(DOV-216303 HCl)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 264.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE. Amitifadine,
a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in
female rats. Eur J Pharmacol. 2015 Oct 5;764:30-7. doi:
10.1016/j.ejphar.2015.06.041. PubMed PMID: 26101069; PubMed Central PMCID:
PMC4941618.


2: Miller LL, Leitl MD, Banks ML, Blough BE, Negus SS. Effects of the triple
monoamine uptake inhibitor amitifadine on pain-related depression of behavior and
mesolimbic dopamine release in rats. Pain. 2015 Jan;156(1):175-84. doi:
10.1016/j.pain.0000000000000018. PubMed PMID: 25599313; PubMed Central PMCID:
PMC4351716.


3: van Heesch F, Prins J, Konsman JP, Korte-Bouws GA, Westphal KG, Rybka J,
Olivier B, Kraneveld AD, Korte SM. Lipopolysaccharide increases degradation of
central monoamines: an in vivo microdialysis study in the nucleus accumbens and
medial prefrontal cortex of mice. Eur J Pharmacol. 2014 Feb 15;725:55-63. doi:
10.1016/j.ejphar.2014.01.014. PubMed PMID: 24444442.


4: Sørensen G, Husum H, Brennum LT, Bundgaard C, Montezinho LC, Mørk A, Wörtwein
G, Woldbye DP. Addiction-related effects of DOV 216,303 and cocaine: A
comparative study in the mouse. Basic Clin Pharmacol Toxicol. 2014
Jun;114(6):451-9. doi: 10.1111/bcpt.12182. PubMed PMID: 24314270.


5: Bijlsma EY, Chan JS, Olivier B, Veening JG, Millan MJ, Waldinger MD, Oosting
RS. Sexual side effects of serotonergic antidepressants: mediated by inhibition
of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014
Jun;121:88-101. doi: 10.1016/j.pbb.2013.10.004. Review. PubMed PMID: 24128918.


6: O'Tousa DS, Warnock KT, Matson LM, Namjoshi OA, Linn MV, Tiruveedhula VV,
Halcomb ME, Cook J, Grahame NJ, June HL. Triple monoamine uptake inhibitors
demonstrate a pharmacologic association between excessive drinking and
impulsivity in high-alcohol-preferring (HAP) mice. Addict Biol. 2015
Mar;20(2):236-47. doi: 10.1111/adb.12100. PubMed PMID: 24118509; PubMed Central
PMCID: PMC3984927.


7: Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD. Biopharmaceutical
characterization, metabolism, and brain penetration of the triple reuptake
inhibitor amitifadine. Drug Metab Lett. 2013 Mar;7(1):23-33. PubMed PMID:
23826879.


8: Prins J, Kenny PJ, Doomernik I, Schreiber R, Olivier B, Mechiel Korte S. The
triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain
reward activity as measured by intracranial self-stimulation in rats. Eur J
Pharmacol. 2012 Oct 15;693(1-3):51-6. doi: 10.1016/j.ejphar.2012.07.047. PubMed
PMID: 23010469.


9: Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June
HL. Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and
negative affect in an animal model of co-occurring alcoholism and depression
symptomatology. Pharmacol Biochem Behav. 2012 Nov;103(1):111-8. PubMed PMID:
22884707; PubMed Central PMCID: PMC3537915.


10: Prickaerts J, De Vry J, Boere J, Kenis G, Quinton MS, Engel S, Melnick L,
Schreiber R. Differential BDNF responses of triple versus dual reuptake
inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and
prefrontal cortex. J Mol Neurosci. 2012 Sep;48(1):167-75. doi:
10.1007/s12031-012-9802-9. PubMed PMID: 22581450; PubMed Central PMCID:
PMC3413810.


11: Golembiowska K, Kowalska M, Bymaster FP. Effects of the triple reuptake
inhibitor amitifadine on extracellular levels of monoamines in rat brain regions
and on locomotor activity. Synapse. 2012 May;66(5):435-44. doi:
10.1002/syn.21531. PubMed PMID: 22213370.


12: Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M.
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in
the treatment of patients with major depressive disorder: a randomized,
double-blind, placebo-controlled trial. J Psychiatr Res. 2012 Jan;46(1):64-71.
doi: 10.1016/j.jpsychires.2011.09.003. PubMed PMID: 21925682.


13: Czobor P, Skolnick P. The secrets of a successful clinical trial: compliance,
compliance, and compliance. Mol Interv. 2011 Apr;11(2):107-10. doi:
10.1124/mi.11.2.8. PubMed PMID: 21540470; PubMed Central PMCID: PMC3109858.


14: Prins J, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Olivier B,
Korte SM. The potential and limitations of DOV 216,303 as a triple reuptake
inhibitor for the treatment of major depression: a microdialysis study in
olfactory bulbectomized rats. Pharmacol Biochem Behav. 2011 Jan;97(3):444-52.
doi: 10.1016/j.pbb.2010.10.001. PubMed PMID: 20934452.


15: Caldarone BJ, Paterson NE, Zhou J, Brunner D, Kozikowski AP, Westphal KG,
Korte-Bouws GA, Prins J, Korte SM, Olivier B, Ghavami A. The novel triple
reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile
without locomotor stimulant or sensitization properties. J Pharmacol Exp Ther.
2010 Dec;335(3):762-70. doi: 10.1124/jpet.110.174011. PubMed PMID: 20864506;
PubMed Central PMCID: PMC2993553.


16: Paterson NE, Balci F, Campbell U, Olivier BE, Hanania T. The triple reuptake
inhibitor DOV216,303 exhibits limited antidepressant-like properties in the
differential reinforcement of low-rate 72-second responding assay, likely due to
dopamine reuptake inhibition. J Psychopharmacol. 2011 Oct;25(10):1357-64. doi:
10.1177/0269881110364272. PubMed PMID: 20305042.


17: Prins J, Denys DA, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R,
Groenink L, Olivier B, Korte SM. The putative antidepressant DOV 216,303, a
triple reuptake inhibitor, increases monoamine release in the prefrontal cortex
of olfactory bulbectomized rats. Eur J Pharmacol. 2010 May 10;633(1-3):55-61.
doi: 10.1016/j.ejphar.2010.02.009. PubMed PMID: 20153745.


18: Guiard BP, Chenu F, El Mansari M, Blier P. Characterization of the
electrophysiological properties of triple reuptake inhibitors on monoaminergic
neurons. Int J Neuropsychopharmacol. 2011 Mar;14(2):211-23. doi:
10.1017/S1461145710000076. PubMed PMID: 20149268.


19: Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, Schreiber
R, Hanania T, Snoeren EM, Waldinger M, Olivier B. The triple monoaminergic
reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory
bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol. 2008
Dec;18(12):908-16. doi: 10.1016/j.euroneuro.2008.07.011. PubMed PMID: 18789657.


20: Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong
TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS. The triple uptake
inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane
hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent
models of diet-induced obesity. J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26.
PubMed PMID: 18089843.